(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 December 2009 (03.12.2009)

PCT

(10) International Publication Number
WO 2009/143611 A1

(51) International Patent Classification:
A61K 35/76 (2006.01) *A61K 33/24* (2006.01)
A61K 31/555 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/CA2009/000721

(22) International Filing Date:
27 May 2009 (27.05.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/056,292 27 May 2008 (27.05.2008) US
61/113,791 12 November 2008 (12.11.2008) US

(71) Applicant *(for all designated States except US)*: **ONCOLYTICS BIOTECH INC.** [CA/CA]; Suite 210, 1167 Kensington Crescent, N.W., Calgary, Alberta T2N 1X7 (CA).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **COFFEY, Matthew C.** [CA/CA]; 2231 Bowness Road, N.W., Calgary, Alberta T2N 3L4 (CA). **THOMPSON, Bradley G.** [CA/CA]; 1775 - 7th Avenue, N.W., Calgary, Ontario T2N 0Z5 (CA). **PANDHA, Hardev** [GB/GB]; 164 Castelnau, Barnes, London SW13 9DH (GB).

(74) Agent: **TORYS LLP**; Suite 3000, 79 Wellington Street West, Box 270, TD Centre, Toronto, Ontario M5K 1N2 (CA).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

[Continued on next page]

(54) Title: ABROGATING PROINFLAMMATORY CYTOKINE PRODUCTION DURING ONCOLYTIC REOVIRUS THERAPY




FIG. 1A

(57) Abstract: Provided herein are methods for treating a proliferative disorder in a subject comprising administering to the subject one or more reoviruses and one or more agents that modulate expression or activity of pro-inflammatory cytokines. For example, the agents may inhibit expression or activity of pro-inflammatory cytokines.

WO 2009/143611 A1

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*